Biosimilars – Keys to Success in the Pharmacy Benefit
11:00 a.m. - 12:00 p.m.
The market entry of biosimilar insulin and multiple versions of biosimilar Humira have signaled a new era in biosimilar competition. As primarily pharmacy-benefit products, the opportunities and challenges for adoption can vary from those facing provider-administered biosimilars. This panel will review the state of the market and any lessons from the launches to date.
Principal – US Market Access Strategy, IQVIA Institute for Human Data Science
CEO, Matrix Global Advisors
Vice President, Government Affairs and Policy, Fresenius Kabi, Inc.
Melissa Andel, MPP
Principal, CommonHealth Solutions